Former Attorney General Pam Bondi has been diagnosed with thyroid cancer, underwent surgery weeks ago, and is now recovering while preparing to take on a new role advising the White House on artificial intelligence policy.
Bondi, 60, received the diagnosis shortly after President Trump removed her from her post atop the Department of Justice in early April. She has been undergoing treatment quietly, and the news became public only after Katie Miller, a podcast host and former White House adviser, disclosed Bondi's condition on social media, writing that Bondi "has been quietly kicking cancer's a** the last few weeks" and that she "has a heart of gold."
Despite the diagnosis, Bondi is not stepping away from public life. Trump has tapped her to join the Presidential Council of Advisors on Science and Technology, the White House advisory body known as PCAST, where she will help coordinate between the federal government and technology executives on AI policy.
The timeline is striking. Bondi left the Department of Justice at the beginning of April after Trump ousted her. Shortly after that departure, she learned she had thyroid cancer. Surgery followed within weeks.
Bondi told CBS News she is undergoing treatment and said she was excited to enter a role in the private sector. No details about the specific type or stage of her cancer have been made public, nor has her treating facility been identified.
The broader medical picture offers reason for cautious optimism. The Cleveland Clinic reports that the most common forms of thyroid cancer, papillary and follicular, carry a five-year survival rate of more than 98 percent. The New York Post noted that thyroid cancer is more common in women, with a diagnosis rate nearly three times higher than in men, and that Bondi is the second Trump official to face the disease, following Jared Kushner's diagnosis during the first administration.
Vice President JD Vance offered a public statement of support for Bondi's continued involvement with the administration:
"Pam has been an enormously valuable asset to the president's team, and I'm thrilled for her and for all of us that she's going to remain involved in confronting some of the most important issues the administration faces."
Bondi's departure from the Justice Department was part of a broader wave of cabinet shake-ups earlier this year. She was one of four cabinet members to leave their positions in 2025. Former Homeland Security Secretary Kristi Noem and former Labor Secretary Lori Chavez-DeRemer were also removed. Tulsi Gabbard resigned last week as Director of National Intelligence, citing her husband's recent bone cancer diagnosis.
Bondi's removal drew significant attention at the time. She had been fiercely loyal to Trump since his first term, and her firing surprised many in Washington.
After the announcement, Bondi publicly defended her record at the Justice Department, pointing to her work there as evidence of her commitment to the administration's priorities.
Now she moves to PCAST, which Trump established by executive order in January 2025. The order described the council's purpose as an effort to "unite the brightest minds from academia, industry, and government to guide our Nation through this critical moment by charting a path forward for American leadership in science and technology."
The council's first members were announced in March and include some of the most prominent names in American technology: Google co-founder Sergey Brin, Meta CEO Mark Zuckerberg, Oracle co-founder Larry Ellison, and Nvidia CEO Jensen Huang. Fox News reported that Bondi's role on PCAST will focus on helping coordinate between the federal government and those technology executives.
Bondi's health battle comes as she faces continued scrutiny over her tenure at the DOJ. She is scheduled to testify Friday before the House Oversight Committee regarding her handling of the Jeffrey Epstein files.
The Department of Justice released a set of Epstein-related documents during Bondi's time as Attorney General. Both Bondi and Trump received bipartisan criticism over the release. Some Democratic lawmakers argued that important files were withheld from the public.
The specifics of what the committee intends to press Bondi on remain unclear. But the hearing ensures that even as she battles cancer and transitions to a new advisory role, the political spotlight will not dim.
It is worth noting the broader pattern of personnel turbulence in the Trump administration. Four cabinet-level departures in a matter of months is a significant pace. Trump moved quickly to install Todd Blanche as acting Attorney General after Bondi's exit, and similar swift replacements followed other departures.
That churn has drawn questions from both allies and critics about stability at the top of the executive branch. The administration has pushed back on those characterizations.
Bondi's situation is distinct from the others, though. She is not disappearing from the president's orbit. Her appointment to PCAST signals that Trump still values her involvement, and that Bondi, even while undergoing cancer treatment, intends to remain in the arena.
Several important details remain undisclosed. Bondi has not publicly identified the stage or specific type of her thyroid cancer. Her treating physicians and the facility where she had surgery have not been named. Whether her PCAST appointment was arranged before or after her diagnosis is also unclear.
Newsmax reported that Bondi is recovering and continues to support the administration's agenda despite her health challenges. The general prognosis for thyroid cancer patients is favorable, but without knowing the specifics of Bondi's case, any projection remains speculative.
There is also the question of how her health will affect Friday's testimony. Bondi has given no indication she plans to delay or skip the House Oversight appearance. If she shows up and takes questions while weeks out from cancer surgery, it will be a testament to the kind of toughness that defined her time at DOJ, whatever one thinks of how that time ended.
The administration has seen mounting pressure on multiple fronts regarding personnel decisions in recent months, and Bondi's cancer diagnosis adds a personal dimension to what has been a politically charged stretch of departures.
Washington rarely pauses for anyone's personal battles. Bondi, it appears, isn't asking it to.